Intensive endoscopic resection for downstaging of polyp burden in patients with familial adenomatous polyposis (J-FAPP Study III): a multicenter prospective interventional study

Abstract

Background Total colectomy is the standard treatment for familial adenomatous polyposis (FAP). Recently, an increasing number of young patients with FAP have requested the postponement of surgery or have refused to undergo surgery. We aimed to evaluate the effectiveness of intensive endoscopic removal for downstaging of polyp burden (IDP) in FAP.

Method A single-arm intervention study was conducted at 22 facilities. Participants were patients with FAP, aged ≥ 16 years, who had not undergone colectomy or who had undergone colectomy but had ≥ 10 cm of large intestine remaining. For IDP, colorectal polyps of ≥ 10 mm were removed, followed by polyps of ≥ 5 mm. The primary end point was the presence/absence of colectomy during a 5-year intervention period.

Results 222 patients were eligible, of whom 166 had not undergone colectomy, 46 had undergone subtotal colectomy with ileorectal anastomosis, and 10 had undergone partial resection of the large intestine. During the intervention period, five patients (2.3 %, 95 % confidence interval [CI] 0.74 %–5.18 %) underwent colectomy, and three patients died. Completion of the 5-year intervention period without colectomy was confirmed in 150 /166 patients who had not undergone colectomy (90.4 %, 95 %CI 84.8 %–94.4 %) and in 47 /56 patients who had previously undergone colectomy (83.9 %, 95 %CI 71.7 %–92.4 %).

Conclusion IDP in patients with mild-to-moderate FAP could have the potential to be a useful means of preventing colorectal cancer without implementing colectomy. However, if the IDP protocol was proposed during a much longer term, it may not preclude the possibility that a large proportion of colectomies may still need to be performed.

• References

• 1 Iwama T, Tamura K, Morita T. et al. A clinical overview of familial adenomatous polyposis derived from the database of the polyposis registry of Japan. Int J Clin Oncol 2004; 9: 308-316
• 2 Vasen HF, Möslein G, Alonso A. et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57: 704-713
• 3 Smith AJ, Lewis JJ, Merchant NB. et al. Surgical management of intra-abdominal desmoid tumours. Br J Surg 2000; 87: 608-613
• 4 Nielsen M, Hes FJ, Nagengast FM. et al. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet 2007; 71: 427-433
• 5 Tomita N, Ishida H, Tanakaya K. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines: 2020 for the Clinical Practice of Hereditary Colorectal Cancer. Int J Clin Oncol 2021; 26; 1353-1419
• 6 Koskenvuo L, Renkonen-Sinisalo L, Jarvinen HJ. et al. Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. Int J Colorectal Dis 2014; 29: 225-230
• 7 Campos FG, Perez RO, Imperiale AR. et al. Surgical treatment of familial adenomatous polyposis: ileorectal anastomosis or restorative proctolectomy?. Arq Gastroenterol 2009; 46: 294-299
• 8 Winawer SJ, Zauber AG, Ho MN. et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981
• 9 Vogelstein B, Fearon ER, Hamilton SR. et al. Genetic alterations during colorectal-tumor development. New Engl J Med 1988; 319: 525-532
• 10 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 2000; 61: 759-767
• 11 Pasquer A, Benech N, Pioche M. et al. Prophylactic colectomy and rectal preservation in FAP: systematic endoscopic follow-up and adenoma destruction changes natural history of polyposis. Endosc Int Open 2021; 9: E1014-E1022
• 12 Ishikawa H, Mutoh M, Iwama T. et al. Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy 2016; 48: 51-55
• 13 Tokudome S, Goto C, Imaeda N. et al. Development of a data-based short food frequency questionnaire for assessing nutrient intake by middle-aged Japanese. Asian Pacific J Cancer Prev 2004; 5: 40-43
• 14 Ishikawa H, Mutoh M, Sato Y. et al. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol 2021; 6: 474-481
• 15 Campos FG. Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. World J Gastroenterol 2014; 20: 16620-16629
• 16 Sinha A, Burns EM, Latchford A. et al. Risk of desmoid formation after laparoscopic versus open colectomy and ileorectal anastomosis for familial adenomatous polyposis. BJS Open 2018; 2: 452-455
• 17 Chittleborough TJ, Warrier SK, Heriot AG. et al. Dispelling misconceptions in the management of familial adenomatous polyposis. ANZ J Surg 2017; 87: 441-445
• 18 Lynch PM, Morris JS, Wen S. et al. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 2016; 84: 115-25.e4
• 19 Septer S, Lawson CE, Anant S. et al. Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate. Fam Cancer 2016; 15: 477-485